See more : Nan Liu Enterprise Co., Ltd. (6504.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Tekla Life Sciences Investors (HQL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tekla Life Sciences Investors, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- EKO International Corp. (EKNL) Income Statement Analysis – Financial Results
- FURYU Corporation (6238.T) Income Statement Analysis – Financial Results
- Deep Yellow Limited (DYLLF) Income Statement Analysis – Financial Results
- DTCOM – Direct to Company S.A. (DTCY3.SA) Income Statement Analysis – Financial Results
- Silvergate Capital Corporation (SI-PA) Income Statement Analysis – Financial Results
Tekla Life Sciences Investors (HQL)
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.69M | 23.52M | -103.25M | 65.69M | 124.08M | -69.34M | 29.82M | 69.81M | 6.29M | 1.32M | 876.79K | 516.76K | 2.14M | 570.00K | 1.82M | 460.00K | 1.67M | 2.88M | 2.30M | 890.00K | 320.00K | 610.00K | 940.00K | 1.77M | 140.00K | 320.00K | 420.00K |
| Cost of Revenue | 0.00 | 5.24M | 5.55M | 6.08M | 5.21M | 5.00M | 4.77M | 4.61M | 4.95M | 5.65M | 4.14M | 3.10M | 2.48M | 3.02M | 2.99M | 2.85M | 3.76M | 3.62M | 2.93M | 2.81M | 2.78M | 2.44M | 2.86M | 3.26M | 1.64M | 1.63M | 1.60M |
| Gross Profit | 86.69M | 18.28M | -108.80M | 59.61M | 118.88M | -74.35M | 25.05M | 65.20M | 1.34M | -4.33M | -3.26M | -2.58M | -335.50K | -2.45M | -1.17M | -2.39M | -2.09M | -740.00K | -630.00K | -1.92M | -2.46M | -1.83M | -1.92M | -1.49M | -1.50M | -1.31M | -1.18M |
| Gross Profit Ratio | 100.00% | 77.71% | 105.37% | 90.75% | 95.80% | 107.22% | 84.00% | 93.40% | 21.34% | -327.02% | -372.18% | -499.89% | -15.64% | -429.82% | -64.29% | -519.57% | -125.15% | -25.69% | -27.39% | -215.73% | -768.75% | -300.00% | -204.26% | -84.18% | -1,071.43% | -409.38% | -280.95% |
| Research & Development | 0.00 | 0.00 | -3.28 | 1.43 | 3.15 | -1.84 | 0.80 | 1.46 | -1.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | 5.23M | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | -1.89 | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Other Expenses | 85.35M | 22.62M | 275.97K | 313.69K | 278.66K | 259.76K | 466.64K | 423.33K | 20.74M | 143.44K | 130.00K | 150.00K | 200.00K | 200.00K | 160.00K | 170.00K | 140.00K | 250.00K | 160.00K | 150.00K | 80.00K | 60.00K | 120.00K | 110.00K | 10.00K | 40.00K | 290.00K |
| Operating Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 1.16M | 1.26M | 13.35M | 39.18M | 88.39M | 84.13M | 75.49M | 1.35M | 790.00K | 760.00K | 820.00K | 970.00K | 710.00K | 660.00K | 610.00K | 510.00K | 590.00K | 450.00K | 240.00K | 230.00K | 290.00K |
| Cost & Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 5.59M | 5.56M | 1.34M | 39.18M | 88.39M | 84.13M | 75.49M | 4.37M | 3.78M | 3.61M | 4.58M | 4.59M | 3.64M | 3.47M | 3.39M | 2.95M | 3.45M | 3.71M | 1.88M | 1.86M | 1.89M |
| Interest Income | 1.04M | 204.45K | 50.09K | 0.00 | 164.80K | 216.70K | 90.71K | 90.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27M | 72.43M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 0.00 | 27.60M | 2.99M | 4.14M | 2.11M | 2.88M | 3.61M | 3.88M | 3.79M | 4.72M | 3.77M | 3.17M | 1.28M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| EBITDA | 0.00 | 22.35M | -104.61M | 64.54M | 123.06M | -70.47M | 28.67M | 68.56M | 0.00 | 0.00 | 0.00 | 0.00 | 78.91M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| EBITDA Ratio | 0.00% | 95.03% | 101.31% | 98.24% | 99.17% | 101.64% | 204.33% | 201.96% | 289.30% | 3,419.13% | 10,610.66% | 16,993.50% | 3,679.80% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Operating Income | 0.00 | -5.24M | -104.60M | 64.53M | 123.05M | -70.48M | -3.61M | -3.88M | -3.79M | -4.72M | -3.77M | -3.17M | -1.28M | -3.80M | -1.96M | -3.15M | -2.92M | -1.71M | -1.34M | -2.59M | -3.07M | -2.34M | -2.52M | -1.94M | -1.75M | -1.53M | -1.47M |
| Operating Income Ratio | 0.00% | -22.29% | 101.31% | 98.24% | 99.17% | 101.64% | -12.10% | -5.56% | -60.25% | -357.04% | -429.50% | -613.43% | -59.85% | -666.67% | -107.69% | -684.78% | -174.85% | -59.38% | -58.26% | -291.01% | -959.38% | -383.61% | -268.09% | -109.60% | -1,250.00% | -478.13% | -350.00% |
| Total Other Income/Expenses | 85.30M | 27.60M | -101.61M | 6.08M | 5.21M | -67.60M | 32.61M | 72.74M | -8.12M | 45.22M | 93.03M | 87.82M | 78.91M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| Income Before Tax | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Income Before Tax Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.33% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Income Tax Expense | 0.00 | 0.00 | -2.99M | -4.15M | -2.13M | -2.88M | 1.00 | 3.00 | 26.32M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Net Income Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.30% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| EPS | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | 3.21 | 1.00 | 2.06 | 4.70 | 5.65 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| EPS Diluted | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.23 | 3.21 | 20.74M | 2.06 | 4.70 | 5.64 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| Weighted Avg Shares Out | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 22.41M | 21.36M | -11.91M | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
| Weighted Avg Shares Out (Dil) | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 23.30M | 21.36M | -0.57 | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
Tekla Capital Management LLC Announces Closing of Transaction With abrdn
Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic...
Tekla Life Sciences Investors Paid Distribution
BOSTON--(BUSINESS WIRE)--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary...
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth of biotech stocks thus has resulted in a huge price...
Tekla Life Sciences Investors Declares Distribution
BOSTON--(BUSINESS WIRE)--On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is September 29, 2023. The Fund will trade ex-distribution on...
Tekla Funds Announce Adjournment of Special Meetings
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint special meetings of shareholders on August 14, 2023 (“Special Meetings”) were adjourned...
HQL: 13% Discount Creates An Opportunity
Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.
HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield
HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.
Equity CEFs: Top Picks For 2023
2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to...
5 Best CEFs To Buy This Month (December 2022)
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad market....
Equity CEFs: What's Going On With Tekla's HQH And HQL?
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping...
Source: https://incomestatements.info
Category: Stock Reports